Literature DB >> 14711197

Improvement of ventricular arrhythmia by octreotide treatment in acromegalic cardiomyopathy.

Hidetada Tachibana1, Hiroyuki Yamaguchi, Shigeru Abe, Takayuki Sato, Sumito Inoue, Shuichi Abe, Michiyasu Yamaki, Isao Kubota.   

Abstract

We report a case of acromegalic cardiomyopathy in a 46-year-old Japanese man with pituitary adenoma. Increased secretion of growth hormone and insulin-like growth factor I were detected. He had left ventricular hypertrophy, impaired cardiac function, and frequent ventricular premature complexes. After 2-month treatment with octreotide, a long-acting somatostatin analogue, levels of both hormones were decreased. At the same time, left ventricular hypertrophy (intraventricular septal thickness: 22.5 to 17.8 mm), cardiac function (ejection fraction: 38 to 50%), and frequency of ventricular premature complexes (17,249 to 2,882 beats a day) were improved. Transsphenoidal surgery was then safely performed. Treatment with octreotide is thought to have some effect on improvement of ventricular arrhythmia in acromegalic heart.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14711197     DOI: 10.1536/jhj.44.1027

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  2 in total

1.  QT dispersion in patients with acromegaly.

Authors:  Mustafa Unubol; Ufuk Eryilmaz; Engin Guney; Mevlut Ture; Cagdas Akgullu
Journal:  Endocrine       Date:  2012-11-13       Impact factor: 3.633

Review 2.  Electrophysiological features in acromegaly: re-thinking the arrhythmic risk?

Authors:  M Parolin; F Dassie; R Vettor; R P Steeds; P Maffei
Journal:  J Endocrinol Invest       Date:  2020-07-06       Impact factor: 4.256

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.